Celon Pharma S.A. (WSE:CLN)
Poland flag Poland · Delayed Price · Currency is PLN
16.94
+0.12 (0.71%)
Nov 4, 2026, 2:58 PM CET

Celon Pharma Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Celon Pharma stock has a consensus rating of "Sell" and an average price target of zł 20.38. The average 1-year stock price forecast is 20.31% higher than the current stock price, while the lowest is zł 16.00 (-5.55%) and the highest is zł 25.20 (+48.76%).

Price Target: zł 20.38 (+20.31%)
Analyst Consensus: Sell

Price Target

Chart
TargetLowAverageMedianHigh
Pricezł 16.00zł 20.38zł 21.00zł 25.20
Change-5.55%+20.31%+23.97%+48.76%

Analyst Ratings

The average analyst rating for Celon Pharma stock is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.

Recommendation Trends

Chart
RatingApr '26May '26Jul '26Aug '26Sep '26Oct '26
Strong Buy111100
Buy000011
Hold222222
Sell000000
Strong Sell222222
Total555555

Financial Forecast

Revenue This Year
276.20M
from 242.21M
Increased by 14.04%
Revenue Next Year
286.87M
from 276.20M
Increased by 3.86%
EPS This Year
1.65
from -1.48
EPS Next Year
-0.28
from 1.65
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
196.09M193.89M214.66M205.55M242.21M276.20M
Revenue Growth
24.54%-1.12%10.72%-4.25%17.83%14.04%
Operating Income
-10.59M-37.90M-28.35M-52.94M-25.02M-6.82M
Net Income
-11.61M-39.28M-28.12M-34.45M-79.36M8.40M
EPS
-----1.481.65
Forward PE
72.9272.9272.9235.8424.1510.27
Dividend / Share
0.290.090.08--0.08
Free Cash Flow
-----30.58M-29.90M
No. Analysts
-----5
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is PLN.

Revenue Forecast

Revenue202620272028
High324.6M
Avg276.2M
Low254.2M

Revenue Growth

Revenue Growth202620272028
High
34.0%
Avg
14.0%
Low
5.0%

EPS Forecast

EPS202620272028
High1.65
Avg1.65
Low1.65

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-